. 2021 Apr 14;12:633821. doi: 10.3389/fphar.2021.633821

TABLE 4.

Current phase of development of Janus kinase inhibitors in systemic autoimmune diseases (based on https://clinicaltrials.gov/accessed on November 11, 2020).

Molecule name; [main target(s) of inhibition]	SLE	SS	DM/PM	SSc	RA
Baricitinib [JAK1, 2]	Phase 3	——	Phase 2 NYR	—	Approved
Baricitinib [JAK1, 2]	R	——	Phase 2 NYR	—	Approved
Filgotinib [JAK1]	Phase 2	Phase 2	—	—	Approved
Filgotinib [JAK1]	R	R	—	—	Approved
Peficitinib [JAK1, 2, 3]	—	—	—	—	Approved
Tofacitinib [JAK 1, 2, 3]	—	—	Phase 1	Phase 1/2	Approved
Tofacitinib [JAK 1, 2, 3]	—	—	C	C	Approved
Upadacitinib [JAK1, (2)]	Phase 2	—	—	—	Approved
Upadacitinib [JAK1, (2)]	R	—	—	—	Approved
Ruxolitinib [JAK1, 2]	—	—	—	—	—

C: completed; DM: dermatomyositis; JAK: Janus kinase; NYR: not yet recruiting; PM: polymyositis, R: recruiting; RA: rheumatoid arthritis; SS: Sjogren syndrome; SSc: systemic sclerosis.